Summary
Highlights
The autonomic nervous system is divided into the sympathetic (fight-or-flight) and parasympathetic (rest-and-digest) systems. These two systems work antagonistically; when one is activated, the other is inhibited. The sympathetic system primarily uses alpha and beta receptors, while the parasympathetic system uses muscarinic and nicotinic receptors. This video will focus primarily on parasympathetic pharmacology due to its high yield for medical exams.
The parasympathetic nervous system controls involuntary visceral organs and has craniosacral outflow, originating from cranial nerves and extending to sacral nerves. Four specific cranial nerves (III, VII, IX, X) have parasympathetic activity, each associated with distinct nuclei and functions such as miosis, accommodation, salivation, and GI/lung secretions. Acetylcholine is the major neurotransmitter of this system.
Muscarinic receptors are crucial for parasympathetic function. M1, M4, and M5 receptors are found in the CNS, controlling cognition (agonists are pro-cognitive, antagonists are anti-cognitive). The M2 receptor is in the heart, causing bradycardia when activated and tachycardia when blocked. M3 receptors are widely distributed: in the urinary tract (bladder contraction/urination vs. bladder relaxation/urinary retention), GI tract (peristalsis vs. decreased peristalsis), exocrine glands (increased secretions vs. decreased secretions/dry mouth), eyes (miosis vs. mydriasis), and airways (bronchoconstriction vs. bronchodilation).
Muscarinic agonists produce cholinergic effects, which are anti-sympathetic (e.g., bradycardia, increased urination, salivation, miosis, bronchoconstriction). Muscarinic antagonists, also known as anticholinergics, produce sympathetic-like effects by blocking muscarinic receptors (e.g., tachycardia, urinary retention, decreased secretions, mydriasis, bronchodilation). Understanding this antagonistic relationship is key to comprehending drug effects.
Anti-cholinergic agents block muscarinic receptors. Examples include atropine (unstable bradycardia, cholinergic poisoning), scopolamine (motion sickness), benztropine and trihexyphenidyl (extrapyramidal side effects, Parkinson's), oxybutynin (overactive bladder), dicyclomine (irritable bowel syndrome), glycopyrrolate (sialorrhea, heart rate control in surgery), and ipratropium/tiotropium (COPD/asthma). Mnemonics are provided to aid memorization.
Parasympathomimetic drugs agonize muscarinic receptors, mimicking acetylcholine. Direct muscarinic agonists bind directly to these receptors. Key examples include bethanechol (urinary retention), carbachol (glaucoma), methacholine (bronchial challenge test for asthma), and pilocarpine (Sjögren's syndrome, dry eyes, cystic fibrosis diagnosis). Many of these drugs have 'chol' in their name, indicating their cholinergic activity. Mnemonics like 'Beth pisses me off' for bethanechol and 'gross stuff on your pillow' for pilocarpine are suggested.
Indirect muscarinic agonists, or acetylcholinesterase inhibitors, block the enzyme that breaks down acetylcholine, thus increasing acetylcholine levels in the synapse and enhancing parasympathetic effects. High-yield examples include physostigmine (atropine overdose, belladonna poisoning), pyridostigmine (myasthenia gravis), edrophonium (myasthenia gravis diagnosis), and donepezil (Alzheimer's disease). Many names contain 'stigmine,' hinting at their action as cholinesterase inhibitors. Donepezil's mnemonic is 'his memory is done' due to its use in Alzheimer's for cognitive improvement.
The video concludes by emphasizing that understanding the underlying physiology of muscarinic receptors and the opposing actions of the sympathetic and parasympathetic nervous systems is more crucial than rote memorization. A strong conceptual framework allows for better comprehension of drug mechanisms and clinical effects on medical exams.